Background Data have been accumulating in the past few years that identify vitiligo as a disorder with systemic implications. Results and methods In this hospital‐based, cross‐sectional, case–control study, 50 patients with non‐segmental vitiligo and 50 age‐ and sex‐matched controls underwent analysis of serum lipid profile, oxidative stress biomarkers and carotid duplex. Hydrogen peroxide (H2O2) and malondialdehyde (MDA) were significantly higher in patients than controls (p‐value < .001, <.001, respectively); on the other hand, total antioxidant capacity (TAC) was significantly lower in patients than controls (p‐value = .001). A significantly higher percentage of patients had hypercholesterolemia and borderline high, high or very high levels of LDL‐C, compared to controls (p‐value = .001 and .001, respectively). Atherosclerotic plaques and increased common carotid intima media thickness were significantly detected in patients versus controls. Discussion Results of the present study suggest that a subset of patients with vitiligo are at a higher risk of developing dyslipidemia and atherosclerosis, which might increase their future risk for the development of cardiovascular disease. Confirmation of these findings would subsequently influence investigative and the treatment strategies in the management plan of vitiligo patients in the near future. Significance Vitiligo patients might be at a higher risk of developing dyslipidemia and atherosclerosis, which might increase their risk for the development of cardiovascular disease necessitating prophylactic measures to improve prognosis. Our results might influence the investigative and treatment strategies in the management plan of vitiligo patients in the near future.

BACKGROUND: Egypt is the country with the greatest number of hepatitis C virus (HCV) genotype 4 infections. The latest mass screening campaign in Egypt in 2018 reported an overall HCV seroprevalence of 4.61% (95% confidence interval 4.61 to 4.62) among the 48,345,948 subjects tested. The prevalence of HCV in the cancer population is estimated to range from 1.5 to 32%. HCV per se might directly influence health-related quality of life (HRQoL), via colonization of microglia in the brain or, indirectly, via the effect of systemic inflammatory cytokines which, in turn, can trigger brain interleukin production. Thus, there is an increased interest about the effect of the dual burden of HCV in cancer patients and its impact on the patients’’ HRQoL. AIM: The study is conducted at the outpatient chemotherapy unit of a university hospital in Egypt, over a period of 6 months to estimate their quality of life (QoL) scores according to the European Organization for Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 v3. MATERIALS AND METHODS: A cross-sectional study was conducted, including all patients referred to the chemotherapy clinic during the study period and proven to be HCV positive. Recruited patients were asked to fill the EORTC QLQ-C30 v3 questionnaire, and data regarding their medical conditions were collected from their medical files. RESULTS: One hundred and sixteen (8.8%) patients were HCV positive. QoL scores were statistically significantly lower from almost all reference values categories published in the EORTC manual.